The profile of sexually transmitted infections of men who have sex with men: A tertiary care center-based comparative cross-sectional study
Conclusions: There was an increasing trend of MSM attending the STI clinic from the year 2017. MSM persons are likely to be younger, unmarried, and have more than two sex partners. The commonest STI among MSM was syphilis. (Source: Indian Journal of Sexually Transmitted Diseases)
Source: Indian Journal of Sexually Transmitted Diseases - December 6, 2023 Category: Infectious Diseases Authors: Balakrishnan Pookkottil Pravitha Priya Prathap Neelakandhan Asokan Thiruthara Sukumaran Sudhiraj Source Type: research
EE286 Cost Effectiveness and Public Health Impact of Implementing Gender-Neutral Vaccination with the 9-Valent Human Papillomavirus Vaccine in Turkiye
This study will assess the cost effectiveness and health impact of inclusion of Gender-Neutral Vaccination (GNV) with 9-Valent HPV (9vHPV) in NIP in Turkiye for individuals aged 11-12 years old. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: B. Akyol Ersoy, E. Ko ç, A. Pavelyev, V. Daniels, D. Ugrekhelidze, S. Malhan, M. Basaran, E. Ozyar, G. Hafiz, P.F. Yumuk, U. Selek, T. Yalti, T. Esen, C. Taskiran, M. Gultekin, M.F. Kose, N. Ozgul Source Type: research
EE590 Assessing Health Outcomes and Cost-Effectiveness of Adult HPV Vaccination in Italy
This study investigates the health outcomes and cost-effectiveness of different vaccination strategies to prevent HPV-related diseases in Italy. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: A. Cherif, C. Palmer, M. Lombardi, S. Boccalini, A. Bechini, C. Salvati, F. Senese Source Type: research
HSD95 Unmet Needs and Value Proposition for Genital Warts Novel Treatments: Payer Perception
This study aimed to explore payer perception of the unmet needs related to the treatment of Genital Warts (GW) and investigate the perceived key elements required for a new GW treatment to be of interest and significantly improve the therapeutic landscape. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M.A. Lopez Pont Source Type: research
Vulval lymphangioma circumscriptum as painful papulovesicles mimicking genital warts
Actas Dermosifiliogr. 2023 Nov 24:S0001-7310(23)00927-4. doi: 10.1016/j.ad.2023.02.035. Online ahead of print.NO ABSTRACTPMID:38008245 | DOI:10.1016/j.ad.2023.02.035 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - November 26, 2023 Category: Dermatology Authors: L Corbella-Bagot A Garc ía-Herrera P Fust é-Brull I Fuertes de Vega Source Type: research
Vulval lymphangioma circumscriptum as painful papulovesicles mimicking genital warts
Actas Dermosifiliogr. 2023 Nov 24:S0001-7310(23)00927-4. doi: 10.1016/j.ad.2023.02.035. Online ahead of print.NO ABSTRACTPMID:38008245 | DOI:10.1016/j.ad.2023.02.035 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - November 26, 2023 Category: Dermatology Authors: L Corbella-Bagot A Garc ía-Herrera P Fust é-Brull I Fuertes de Vega Source Type: research
Vulval lymphangioma circumscriptum as painful papulovesicles mimicking genital warts
Actas Dermosifiliogr. 2023 Nov 24:S0001-7310(23)00927-4. doi: 10.1016/j.ad.2023.02.035. Online ahead of print.NO ABSTRACTPMID:38008245 | DOI:10.1016/j.ad.2023.02.035 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - November 26, 2023 Category: Dermatology Authors: L Corbella-Bagot A Garc ía-Herrera P Fust é-Brull I Fuertes de Vega Source Type: research
Vulval lymphangioma circumscriptum as painful papulovesicles mimicking genital warts
Actas Dermosifiliogr. 2023 Nov 24:S0001-7310(23)00927-4. doi: 10.1016/j.ad.2023.02.035. Online ahead of print.NO ABSTRACTPMID:38008245 | DOI:10.1016/j.ad.2023.02.035 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - November 26, 2023 Category: Dermatology Authors: L Corbella-Bagot A Garc ía-Herrera P Fust é-Brull I Fuertes de Vega Source Type: research
Vulval lymphangioma circumscriptum as painful papulovesicles mimicking genital warts
Actas Dermosifiliogr. 2023 Nov 24:S0001-7310(23)00927-4. doi: 10.1016/j.ad.2023.02.035. Online ahead of print.NO ABSTRACTPMID:38008245 | DOI:10.1016/j.ad.2023.02.035 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - November 26, 2023 Category: Dermatology Authors: L Corbella-Bagot A Garc ía-Herrera P Fust é-Brull I Fuertes de Vega Source Type: research
Vulval lymphangioma circumscriptum as painful papulovesicles mimicking genital warts
Actas Dermosifiliogr. 2023 Nov 24:S0001-7310(23)00927-4. doi: 10.1016/j.ad.2023.02.035. Online ahead of print.NO ABSTRACTPMID:38008245 | DOI:10.1016/j.ad.2023.02.035 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - November 26, 2023 Category: Dermatology Authors: L Corbella-Bagot A Garc ía-Herrera P Fust é-Brull I Fuertes de Vega Source Type: research
Vulval lymphangioma circumscriptum as painful papulovesicles mimicking genital warts
Actas Dermosifiliogr. 2023 Nov 24:S0001-7310(23)00927-4. doi: 10.1016/j.ad.2023.02.035. Online ahead of print.NO ABSTRACTPMID:38008245 | DOI:10.1016/j.ad.2023.02.035 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - November 26, 2023 Category: Dermatology Authors: L Corbella-Bagot A Garc ía-Herrera P Fust é-Brull I Fuertes de Vega Source Type: research
Cantharidin Topical Solution 0.7%: First Approval
This article summarizes the milestones in the development of cantharidin 0.7% topical solution leading to this first approval for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.PMID:38007409 | DOI:10.1007/s40272-023-00600-y (Source: Paediatric Drugs)
Source: Paediatric Drugs - November 25, 2023 Category: Pediatrics Authors: Susan J Keam Source Type: research
Cantharidin Topical Solution 0.7%: First Approval
This article summarizes the milestones in the development of cantharidin 0.7% topical solution leading to this first approval for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.PMID:38007409 | DOI:10.1007/s40272-023-00600-y (Source: Paediatric Drugs)
Source: Paediatric Drugs - November 25, 2023 Category: Pediatrics Authors: Susan J Keam Source Type: research
Cantharidin Topical Solution 0.7%: First Approval
This article summarizes the milestones in the development of cantharidin 0.7% topical solution leading to this first approval for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.PMID:38007409 | DOI:10.1007/s40272-023-00600-y (Source: Paediatric Drugs)
Source: Paediatric Drugs - November 25, 2023 Category: Pediatrics Authors: Susan J Keam Source Type: research
Cantharidin Topical Solution 0.7%: First Approval
This article summarizes the milestones in the development of cantharidin 0.7% topical solution leading to this first approval for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.PMID:38007409 | DOI:10.1007/s40272-023-00600-y (Source: Paediatric Drugs)
Source: Paediatric Drugs - November 25, 2023 Category: Pediatrics Authors: Susan J Keam Source Type: research
